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Effect of FK 506 on Peripheral Blood T -Lymphocyte Subsets in 
Liver Transplant Patients 
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Hayashi, R. Selby, V. Warty, K. Noguchi, Y. Iwaki, and T.E. Starzl 
LTHOUGH the detailed immunosuppressive mecha-
nism of cyclosporine (CyA) differs from that of FK 
both CyA and FK 506 inhibit T-Iymphocyte prolifer-
by blocking production of interleukin-2 (IL-2) either 
ltdirlectly or indirectly.I.:z 
Peripheral T-Iymphocyte subsets appeared to be influ-
... I:ncl=a under the presence of Cy A. 3-S In rat, both CD4 and 
positive T lymphocytes were decreased in the periph-
blood in the presence of FK 506.6 
In this study, we monitored the peripheral T-Iympho-
cyte subsets in orthotopic liver transplant (OL n patients 
~K to evaluate the association between plasma FK 506 trough 
¥ level and T-lymphocyte subsets. 
MATERIALS AND METHODS 
Patients 
. This study consisted of 36 randomly selected plasma samples from 
patients who received OLT at the Presbyterian University Hos-
·.pital, University of Pittsburgh, betwccn May I, 1991 and July 31, 
1991. The initial immunosuppressant was FK 506 with a low-dose 
OKT3, antilymphocyte globulin (ALG), and azathioprine 
were not used. 
Peripheral T-Lymphocyte Subset Monitoring 
Freshly isolated lymphocytes using Ficoll-Hypaque density 
method were stored in liquid nitrogen until the testing. 
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CD3, CD4, and CDS monoclonal antibodies (Becton Dickinson, 
Mountain View, Calif) were used to stain the T-lymphocyte 
subsets as described earlier.7 F ACSean (Becton Dickinson) was 
used for the analysis. 
Plasma FK 506 Trough Levels 
The FK 506 trough levels were measured using the plasma 
isolated from the samples monitored for the T-lymphocyte sub-
sets. The plasma FK 506 trough level was determined by enzyme-
linked immunosorbent assay (ELISA) described by Tamura et al.8 
RESULTS 
FK 506 reduced the proportion of CD3 positive T lympho-
cytes in the peripheral blood, however, the magnitude of 
reduction was not influenced by the plasma FK 506 trough 
level (Fig 1). 
The FK 506-treated patients had a decreased proportion 
of both CD4 and CDS T lymphocytes compared with the 
From the Departments of Pathology and Surgery, University of 
Pittsburgh School of Medicine, DeSoto at O'Hare St, Pittsburgh, 
Pennsylvania. 
Address reprint requests to Thomas E Starzl, MD, PhD. Depart-
mentofSurgery, FalkCllnlc, 3601 Fifth Ave, Pittsburgh, PA 15213. 
~ 1991 by Appleton & Lange 
0041-13451911$3.001 +0 
0 
0 
0 0 0 
0 0 
0 
00 0 0 
0 
0 go 0 00 0 
0 00 0 8 
00 0 0 
0 
0 ll+-----------*-----~----~ 
.1 10 
n: 506 (IIc/1III) 
]0 :l:::::::::::::::::::::: ::::::::::: ::::::::::::: 
::::::::::::::::::::::0: ::::::::::: :::::::::i::: 
................................................. 
........................ ........... ............ . 
........................ ........... ............. . 
20 ::::::::::::::::::::Q:: ::::::::::: ':::::::::::: 
. jj:~:~j~~~mjll gggjgg @jjjjmg 
............................................. 
10 0 0 
0 0 
00 0 
0 
.1 
n: lOG (IIi/ali) 
10 
.1 
IS 
0 
.1 
0 
10 
o ,If I 
0 
0 0 
0 0 
0 
0 00 
8 0 0 a. 0 
0 000 
0 
lit IK(.".) 
o 
o 
o 0 
o 
o 0 
o FIg 1. T-Lymphocyte subsets 
(COO, CD4, and COB) and CD4I 
10 CD8 ratio according to the 
plasma FK 506 trough level. 
Transplantation Proceedings, Vol 23, No 6 (December), 1991: pp 2937-2938 2937 
1 
;, 
il il 
i 
2938 
normal individuals with a few exceptions. Interestingly, 
the most significant suppression of CD4 or CDS proportion 
was observed with a FK 506 plasma trough level of 1 to 3 
ng/mL. 
A trend of higher CD4/CDS ratio was observed as the 
FK 506 trough level was increased, however, it was not 
significant. 
DISCUSSION 
FK 506 not only inhibits early phase of CD4 positive 
T-Iymphocyte activation, it also suppresses CDS positive 
cytotoxic T-Iymphocyte generation. I •9 Our study clearly 
demonstrated a decreased population of both CD4 and 
CDS T lymphocytes. However, the most significant sup-
pression was observed when FK 506 trough level was a 
range of I to 3 ng/mL in either subset. 
The suppression was inconsistent when it was more than 
3 ng/mL. This result differs from the in vitro experiment 
that indicated the dose-dependent efficiency of FK 506.10 
One possible explanation is that the in vitro study primar-
ily focused on the functional study whereas our study 
reflects just cell popUlation. Therefore, the FK 506 trough 
level does not necessarily need to reflect the suppressed 
number of CD4 or CDS positive T lymphocytes. In fact, 
animal studies indicated that a higher incidence of CDS 
positive T cells in the spleen or thymus was observed when 
FK 506 was administered. 11 The time lag between the 
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monitoring results and FK 506 trough levels should not be 
overlooked. 11 
In summary, although further T-lymphocyte studies are 
in order in conjunction with the subset monitoring, a rar~e 
of 1 to 3 ng/mL of plasma trough FK 506 levels seems te Je 
favorable. 
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